Brief: Erasca Doses First Patient In Seacraft-1 Phase 1B Trial Evaluating Naporafenib Plus Trametinib In Patients With Ras Q61x Solid Tumors

Erasca

29/08/2023 13:09

Aug 29 (Reuters) - Erasca Inc  ERAS.O :
    * ERASCA DOSES FIRST PATIENT IN SEACRAFT-1 PHASE 1B TRIAL
EVALUATING NAPORAFENIB PLUS TRAMETINIB IN PATIENTS WITH RAS Q61X
SOLID TUMORS
    * ERASCA INC - INITIAL PHASE 1B COMBINATION DATA FROM
SEACRAFT-1
EXPECTED IN Q2-Q4 2024
    * ERASCA INC - DOSING OF FIRST PATIENT IN PIVOTAL SEACRAFT-2
TRIAL
IN NRAS-MUTANT MELANOMA EXPECTED IN H1 2024
    * ERASCA INC - ANTI-TUMOR ACTIVITY IN PATIENTS WITH NRAS
Q61X
MELANOMA AND KRAS Q61X NSCLC SUPPORTS TISSUE AGNOSTIC
DEVELOPMENT IN RAS Q61X SOLID TUMORS

Source text for Eikon:  ID:nGNX4xJYxQ 
Further company coverage:  ERAS.O